title: Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate.
abstract: OBJECTIVE
  This study examined the effect of an angiostatic agent on the growth of a highly vascularized intraocular tumor.
  
  
  METHODS
  A murine uveal melanoma cell line (99E1) was transplanted intracamerally into athymic nude BALB/c mice. Mice were treated topically three times per day beginning on the day of tumor transplantation and continuing through day 28. Groups included (a) 1% anecortave acetate, (b) vehicle control, or (c) no treatment. Tumor growth was scored clinically according to the volume of anterior chamber occupied by tumor. Intraocular tumor weights were determined on days 10, 14, 21, and 28. The effect of the test agents on tumor cell proliferation was examined in vitro by [3H]thymidine incorporation.
  
  
  RESULTS
  Tumors grew progressively in untreated mice and mice treated with the vehicle; tumors filled the entire eye by day 20 and frequently perforated the globe by day 21. By contrast, tumors treated with anecortave acetate grew significantly slower (P < 0.025) and did not perforate the eye. On days 21 and 28 the net tumor weight of the AL-3789-treated animals was 40% to 30% of controls (P < 0.05). Tumor inhibition was presumably due to the angiostatic properties of anecortave acetate because the compound did not affect tumor cell proliferation in vitro.
  
  
  CONCLUSIONS
  The topical ocular administration of anecortave acetate restricted the growth of a highly vascularized angiogenic intraocular tumor.
authors.affiliation: Alcon Laboratories, Inc., Fort Worth, Texas 76134-2099, USA.
authors.forename: A F
authors.initials: AF
authors.lastname: Clark
authors.forename: J
authors.initials: J
authors.lastname: Mellon
authors.forename: X Y
authors.initials: XY
authors.lastname: Li
authors.forename: D
authors.initials: D
authors.lastname: Ma
authors.forename: H
authors.initials: H
authors.lastname: Leher
authors.forename: R
authors.initials: R
authors.lastname: Apte
authors.forename: H
authors.initials: H
authors.lastname: Alizadeh
authors.forename: S
authors.initials: S
authors.lastname: Hegde
authors.forename: A
authors.initials: A
authors.lastname: McLenaghan
authors.forename: E
authors.initials: E
authors.lastname: Mayhew
authors.forename: T J
authors.initials: TJ
authors.lastname: D'Orazio
authors.forename: J Y
authors.initials: JY
authors.lastname: Niederkorn
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000867:Anterior Chamber / Q000187:drug effects* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006854:Hydrocortisone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008546:Melanoma, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D014407:Tumor Cells, Cultured; D014604:Uveal Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology
chemical_list: C108423:AL 3789; C108424:Anecortave; D006854:Hydrocortisone